Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

TELA Bio, Inc. - Common stock (NQ:TELA)

1.860 +0.140 (+8.14%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about TELA Bio, Inc. - Common stock

< Previous 1 2 3 Next >
TELA Bio Reports Second Quarter 2025 Financial Results
From TELA Bio, Inc.
Via GlobeNewswire
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From TELA Bio, Inc.
Via GlobeNewswire
TELA Bio to Participate in the Canaccord Genuity 45th Annual Growth Conference
From TELA Bio, Inc.
Via GlobeNewswire
TELA Bio to Announce Second Quarter 2025 Financial Results
From TELA Bio, Inc.
Via GlobeNewswire
TELA Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From TELA Bio, Inc.
Via GlobeNewswire
TELA Bio Announces European Commercial Launch of OviTex® Inguinal for Robotic and Laparoscopic Inguinal Hernia Repair
Based on market research, inguinal hernia repair is the most common type of hernia repair 
From TELA Bio, Inc.
Via GlobeNewswire
TELA Bio Appoints Jeffrey Blizard as President
Company Further Strengthens Executive Leadership Team to Drive Next Phase of Growth 
From TELA Bio, Inc.
Via GlobeNewswire
TELA Bio to Participate in the 2025 Jefferies Global Healthcare Conference
From TELA Bio, Inc.
Via GlobeNewswire
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From TELA Bio, Inc.
Via GlobeNewswire
TELA Bio Reports First Quarter 2025 Financial Results
From TELA Bio, Inc.
Via GlobeNewswire
TELA Bio to Announce First Quarter 2025 Financial Results
From TELA Bio, Inc.
Via GlobeNewswire
TELA Bio Announces U.S. Commercial Launch of Larger Sizes of OviTex® PRS for Plastic and Reconstructive Surgery
The OviTex PRS portfolio now includes a larger option than any human acellular dermal matrix product on the market 
From TELA Bio, Inc.
Via GlobeNewswire
TELA Bio Reports Fourth Quarter and Full Year 2024 Financial Results
From TELA Bio, Inc.
Via GlobeNewswire
TELA Bio to Announce Fourth Quarter and Full Year 2024 Financial Results
From TELA Bio, Inc.
Via GlobeNewswire
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From TELA Bio, Inc.
Via GlobeNewswire
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From TELA Bio, Inc.
Via GlobeNewswire
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From TELA Bio, Inc.
Via GlobeNewswire
TELA Bio to Participate in Piper Sandler’s 36th Annual Healthcare Conference
From TELA Bio, Inc.
Via GlobeNewswire
TELA Bio Reports Third Quarter 2024 Financial Results
Reiterates 2024 Revenue Guidance and Expects Recently Implemented Operational Efficiency Improvements to Reduce Operating Expenses in 2025 
From TELA Bio, Inc.
Via GlobeNewswire
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From TELA Bio, Inc.
Via GlobeNewswire
TELA Bio Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
From TELA Bio, Inc.
Via GlobeNewswire
TELA Bio Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
From TELA Bio, Inc.
Via GlobeNewswire
TELA Bio Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
From TELA Bio, Inc.
Via GlobeNewswire
TELA Bio to Announce Third Quarter 2024 Financial Results
From TELA Bio, Inc.
Via GlobeNewswire
TELA Bio Reports Second Quarter 2024 Financial Results and Reiterates Full Year 2024 Revenue Guidance
From TELA Bio, Inc.
Via GlobeNewswire
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From TELA Bio, Inc.
Via GlobeNewswire
TELA Bio to Participate in the Canaccord Genuity 44th Annual Growth Conference
From TELA Bio, Inc.
Via GlobeNewswire
TELA Bio to Announce Second Quarter 2024 Financial Results
From TELA Bio, Inc.
Via GlobeNewswire
TELA Bio Appoints Jeffrey Blizard to its Board of Directors
From TELA Bio, Inc.
Via GlobeNewswire
TELA Bio Appoints Greg Firestone as Chief Commercial Officer
From TELA Bio, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.